Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F MAYO

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Journal of Vascular Surgery|February 26, 2024
Changes in global mortality from aortic aneurysmBrianna M Krafcik, David H Stone, Ming Cai, et al.
Archives of Internal Medicine|July 14, 2004
Management of alcohol withdrawal delirium. An evidence-based practice guidelineMichael F Mayo-Smith, Lee H Beecher, Timothy L Fischer, et al.
Mabs|February 5, 2014
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft modelsKathleen R Whiteman, Holly A Johnson, Michele F Mayo, et al.
Blood|September 5, 2013
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignanciesJutta Deckert, Peter U Park, Sharon Chicklas, et al.
International Journal of Molecular Sciences|April 14, 2026
Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral CenterA Bota-Llorca, B Llombart-Cussac, C Serra-Guillén, et al.
Bioorganic & Medicinal Chemistry|February 6, 2018
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4Sébastien L Degorce, Rana Anjum, Keith S Dillman, et al.
Journal of Medicinal Chemistry|October 18, 2019
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell LymphomaSébastien L Degorce, Rana Anjum, Andrew Bloecher, et al.
Molecular Cancer Therapeutics|May 25, 2016
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating ActivityMichael L Miller, Nathan E Fishkin, Wei Li, et al.
Cancer Research|March 4, 2010
Antibody-maytansinoid conjugates designed to bypass multidrug resistanceYelena V Kovtun, Charlene A Audette, Michele F Mayo, et al.
The Annals of Pharmacotherapy|April 4, 2017
Results of a Regional Effort to Improve Warfarin ManagementAdam J Rose, Angela Park, Christopher Gillespie, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Journal of Vascular Surgery|February 26, 2024
Changes in global mortality from aortic aneurysmBrianna M Krafcik, David H Stone, Ming Cai, et al.
Archives of Internal Medicine|July 14, 2004
Management of alcohol withdrawal delirium. An evidence-based practice guidelineMichael F Mayo-Smith, Lee H Beecher, Timothy L Fischer, et al.
Mabs|February 5, 2014
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft modelsKathleen R Whiteman, Holly A Johnson, Michele F Mayo, et al.
Blood|September 5, 2013
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignanciesJutta Deckert, Peter U Park, Sharon Chicklas, et al.
International Journal of Molecular Sciences|April 14, 2026
Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral CenterA Bota-Llorca, B Llombart-Cussac, C Serra-Guillén, et al.
Bioorganic & Medicinal Chemistry|February 6, 2018
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4Sébastien L Degorce, Rana Anjum, Keith S Dillman, et al.
Journal of Medicinal Chemistry|October 18, 2019
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell LymphomaSébastien L Degorce, Rana Anjum, Andrew Bloecher, et al.
Molecular Cancer Therapeutics|May 25, 2016
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating ActivityMichael L Miller, Nathan E Fishkin, Wei Li, et al.
Cancer Research|March 4, 2010
Antibody-maytansinoid conjugates designed to bypass multidrug resistanceYelena V Kovtun, Charlene A Audette, Michele F Mayo, et al.
The Annals of Pharmacotherapy|April 4, 2017
Results of a Regional Effort to Improve Warfarin ManagementAdam J Rose, Angela Park, Christopher Gillespie, et al.
Pageof 8